Immuron Ltd is an Australian biopharmaceutical company focused on immunotherapy using dairy-derived antibody products for humans. Immuron has a unique and versatile technology platform that can generate a wide range of products, all with a high safety profile. The versatility of Immuron’s platform is a function of its dairy origin of antibodies, which enables Immuron to commercialize its products through a range of regulatory pathways, including prescription (Rx), medical foods, over-the-counter (OTC) medicines, and dietary supplements. The Company currently markets and sells Travelan® for the prevention of travelers’ diarrhea, while its lead product candidate IMM-124E is in multiple Phase 2 clinical trials for non-alcoholic Steatohepatitis (NASH), alcoholic steatohepatitis (ASH), and pediatric non-alcoholic fatty liver disease (NAFLD). These products together with the Company’s other preclinical immunotherapy pipeline products targeting immune-related diseases address a large unmet need in the market.

Immuron’s IMM-124E is in three phase II clinical trials for NASH, ASH, and Pediatric NAFLD. NASH therapies are estimated at a $40 billion global market by 2025, and significant valuations have been afforded to companies in phase II trials for NASH. Intercept Pharmaceuticals had positive phase II results for NASH, leading to an increase in market cap from $1.5 billion to $6.6 billion. Additionally, companies such as Galectin Therapeutics ($86.5 million), Galmed Pharmaceuticals ($116.9 million), Conatus Pharmaceuticals ($177.3 million), and Genfit SA ($767.5 million), are in phase II trials for NASH and have valuations higher than Immuron.

  • Immuron is in three phase II clinical trials for NASH, ASH, and Pediatric NAFLD

  • Positive interim phase II results for NASH; top line results expected in 4Q17-1Q18
    • Phase II trial in NASH is fully randomized; interim data reveals no safety concerns or adverse events for IMM-124E
    • NASH therapies are estimated at a $40 billion global market by 2025
    • 5% of the U.S. population develops NASH, and 25% of the U.S. population has NAFLD, a precursor to NASH

  • Revenue increased 40% to A$1.4 million in FY17, up from A$1.0 million in FY16
    • Current revenue generated from Travelan, an all-natural OTC product for the prevention of travelers’ diarrhea
    • Global market estimate of between $600 million - $1.2 billion for Travelan
    • Currently licensed in the U.S., Australia, Canada, South Africa, Latin America, and several countries in SE Asia

  • IMRN’s IMM-529 program has the potential to be the top therapy for Clostridium Difficile infection (CDI)
    • Phase 1 trials to begin at Hadassah Medical center to enroll patients in 2H17; received approval from Israeli Minister of Health
    • Preclinical results showed 80% efficacy for the prevention and treatment of CDI and 77.8% prevention of infection recurrence in mice

More Information | Company Website

 Disclosure

Investor Contact Info:

RedChip Companies Inc.
1017 Maitland Center Commons Blvd.
Maitland, FL 32751
(407) 644-4256
www.RedChip.com

 

"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President The NASDAQ Stock Market